Atsushi Oba
Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 81 | 2026 | 944 | 13.470 |
Why?
| | Pancreatectomy | 40 | 2026 | 289 | 6.350 |
Why?
| | Carcinoma, Pancreatic Ductal | 22 | 2026 | 297 | 4.770 |
Why?
| | Robotic Surgical Procedures | 16 | 2026 | 210 | 4.190 |
Why?
| | Liver Neoplasms | 25 | 2026 | 776 | 4.080 |
Why?
| | Pancreaticoduodenectomy | 29 | 2026 | 149 | 4.030 |
Why?
| | Hepatectomy | 21 | 2026 | 256 | 3.040 |
Why?
| | Laparoscopy | 13 | 2025 | 487 | 2.460 |
Why?
| | Neoadjuvant Therapy | 21 | 2026 | 475 | 2.340 |
Why?
| | Mesenteric Artery, Superior | 11 | 2026 | 28 | 1.910 |
Why?
| | Portal Vein | 10 | 2025 | 123 | 1.860 |
Why?
| | Mesenteric Veins | 6 | 2025 | 28 | 1.810 |
Why?
| | Bile Duct Neoplasms | 8 | 2026 | 132 | 1.570 |
Why?
| | Colorectal Neoplasms | 12 | 2025 | 874 | 1.510 |
Why?
| | Vascular Surgical Procedures | 7 | 2025 | 352 | 1.470 |
Why?
| | Prognosis | 38 | 2026 | 4351 | 1.430 |
Why?
| | Retrospective Studies | 69 | 2026 | 17438 | 1.190 |
Why?
| | Japan | 10 | 2026 | 149 | 1.170 |
Why?
| | Pancreas | 9 | 2025 | 343 | 1.160 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 17 | 2025 | 1998 | 1.140 |
Why?
| | Gastrectomy | 3 | 2025 | 164 | 1.140 |
Why?
| | CA-19-9 Antigen | 7 | 2026 | 36 | 1.110 |
Why?
| | Gadolinium DTPA | 3 | 2026 | 70 | 1.110 |
Why?
| | Aged | 60 | 2026 | 26432 | 1.060 |
Why?
| | Deoxycytidine | 9 | 2025 | 219 | 1.040 |
Why?
| | Celiac Artery | 5 | 2023 | 19 | 1.000 |
Why?
| | Postoperative Complications | 19 | 2026 | 3034 | 0.940 |
Why?
| | Adenocarcinoma | 8 | 2026 | 927 | 0.920 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2025 | 26 | 0.910 |
Why?
| | Robotics | 2 | 2023 | 89 | 0.880 |
Why?
| | Humans | 125 | 2026 | 146342 | 0.860 |
Why?
| | Middle Aged | 55 | 2026 | 36619 | 0.850 |
Why?
| | Pancreatic Fistula | 7 | 2025 | 35 | 0.850 |
Why?
| | Carcinoma, Hepatocellular | 3 | 2021 | 370 | 0.830 |
Why?
| | Stomach Neoplasms | 1 | 2025 | 128 | 0.810 |
Why?
| | Gastroenterology | 2 | 2023 | 187 | 0.800 |
Why?
| | Gastric Stump | 1 | 2023 | 1 | 0.790 |
Why?
| | Biomarkers, Tumor | 9 | 2026 | 1339 | 0.790 |
Why?
| | Chemotherapy, Adjuvant | 10 | 2026 | 429 | 0.760 |
Why?
| | Aged, 80 and over | 19 | 2026 | 8391 | 0.730 |
Why?
| | Adenoma | 2 | 2025 | 210 | 0.720 |
Why?
| | Survival Rate | 15 | 2026 | 2092 | 0.720 |
Why?
| | Tegafur | 3 | 2025 | 12 | 0.680 |
Why?
| | Oxonic Acid | 3 | 2025 | 13 | 0.680 |
Why?
| | Nomograms | 1 | 2022 | 59 | 0.670 |
Why?
| | Neoplasm Staging | 8 | 2025 | 1488 | 0.660 |
Why?
| | Treatment Outcome | 28 | 2026 | 11821 | 0.650 |
Why?
| | Female | 62 | 2026 | 79499 | 0.640 |
Why?
| | Klatskin Tumor | 3 | 2025 | 18 | 0.640 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2026 | 1160 | 0.630 |
Why?
| | Magnetic Resonance Imaging | 3 | 2026 | 3926 | 0.630 |
Why?
| | Dissection | 6 | 2026 | 58 | 0.630 |
Why?
| | Male | 59 | 2026 | 73396 | 0.620 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 18 | 0.620 |
Why?
| | Drainage | 4 | 2026 | 187 | 0.620 |
Why?
| | Neuroendocrine Tumors | 2 | 2023 | 122 | 0.610 |
Why?
| | Vascular Neoplasms | 1 | 2020 | 19 | 0.610 |
Why?
| | Internationality | 1 | 2020 | 156 | 0.600 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 90 | 0.580 |
Why?
| | Practice Patterns, Physicians' | 3 | 2025 | 1408 | 0.560 |
Why?
| | Duodenal Neoplasms | 3 | 2023 | 26 | 0.550 |
Why?
| | Angiography | 1 | 2018 | 206 | 0.530 |
Why?
| | Cholangiocarcinoma | 3 | 2026 | 110 | 0.510 |
Why?
| | Adult | 34 | 2026 | 41087 | 0.510 |
Why?
| | Neoplasm Invasiveness | 6 | 2025 | 504 | 0.510 |
Why?
| | Patient Compliance | 1 | 2021 | 589 | 0.500 |
Why?
| | Multidetector Computed Tomography | 1 | 2017 | 40 | 0.500 |
Why?
| | Operative Time | 6 | 2026 | 195 | 0.470 |
Why?
| | Thrombosis | 2 | 2024 | 398 | 0.460 |
Why?
| | Biliary Tract Neoplasms | 2 | 2025 | 30 | 0.440 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.440 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.440 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2025 | 20 | 0.430 |
Why?
| | Polyglycolic Acid | 2 | 2025 | 44 | 0.430 |
Why?
| | Surgical Mesh | 2 | 2025 | 54 | 0.420 |
Why?
| | Common Bile Duct Neoplasms | 2 | 2025 | 28 | 0.400 |
Why?
| | DNA Damage | 1 | 2017 | 439 | 0.400 |
Why?
| | Ultrasonography | 1 | 2018 | 788 | 0.400 |
Why?
| | Ampulla of Vater | 2 | 2025 | 40 | 0.400 |
Why?
| | Proportional Hazards Models | 5 | 2026 | 1331 | 0.390 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 2219 | 0.380 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2025 | 57 | 0.370 |
Why?
| | Precision Medicine | 1 | 2016 | 462 | 0.350 |
Why?
| | Fluorouracil | 7 | 2025 | 231 | 0.340 |
Why?
| | Contrast Media | 3 | 2026 | 493 | 0.340 |
Why?
| | Diabetes Mellitus | 3 | 2025 | 1101 | 0.340 |
Why?
| | Embolization, Therapeutic | 2 | 2024 | 246 | 0.330 |
Why?
| | Blood Loss, Surgical | 3 | 2026 | 117 | 0.320 |
Why?
| | Jejunum | 3 | 2024 | 36 | 0.310 |
Why?
| | Paclitaxel | 7 | 2025 | 260 | 0.310 |
Why?
| | Leucovorin | 6 | 2025 | 98 | 0.310 |
Why?
| | Follow-Up Studies | 11 | 2026 | 5439 | 0.310 |
Why?
| | Margins of Excision | 2 | 2026 | 55 | 0.290 |
Why?
| | Diarrhea | 3 | 2026 | 190 | 0.290 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2025 | 196 | 0.290 |
Why?
| | Transcription Factors | 1 | 2017 | 1730 | 0.280 |
Why?
| | Sweden | 2 | 2025 | 114 | 0.260 |
Why?
| | Disease-Free Survival | 3 | 2025 | 778 | 0.260 |
Why?
| | Hepatic Veins | 2 | 2024 | 28 | 0.250 |
Why?
| | Splenic Artery | 2 | 2024 | 13 | 0.250 |
Why?
| | Antigens, Neoplasm | 2 | 2026 | 271 | 0.250 |
Why?
| | Incisional Hernia | 1 | 2026 | 8 | 0.240 |
Why?
| | Abdominal Wound Closure Techniques | 1 | 2026 | 8 | 0.240 |
Why?
| | Carcinoma in Situ | 1 | 2026 | 45 | 0.240 |
Why?
| | Fasciotomy | 1 | 2026 | 24 | 0.240 |
Why?
| | Collateral Circulation | 1 | 2025 | 20 | 0.230 |
Why?
| | Albumins | 5 | 2025 | 120 | 0.230 |
Why?
| | Hemostasis, Surgical | 1 | 2025 | 25 | 0.230 |
Why?
| | Peritoneal Lavage | 1 | 2025 | 8 | 0.230 |
Why?
| | Renal Veins | 1 | 2025 | 16 | 0.230 |
Why?
| | Leiomyosarcoma | 1 | 2025 | 30 | 0.230 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 365 | 0.230 |
Why?
| | Surgical Stapling | 1 | 2025 | 14 | 0.230 |
Why?
| | Anatomic Landmarks | 1 | 2025 | 31 | 0.220 |
Why?
| | Abdominal Neoplasms | 1 | 2025 | 48 | 0.220 |
Why?
| | Pericardium | 1 | 2025 | 59 | 0.220 |
Why?
| | Vena Cava, Inferior | 1 | 2025 | 80 | 0.220 |
Why?
| | Splenomegaly | 1 | 2024 | 15 | 0.220 |
Why?
| | Surgery, Computer-Assisted | 1 | 2025 | 87 | 0.210 |
Why?
| | Caveolin 1 | 1 | 2024 | 20 | 0.210 |
Why?
| | Chemoradiotherapy | 2 | 2025 | 238 | 0.210 |
Why?
| | Induction Chemotherapy | 1 | 2024 | 87 | 0.210 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 76 | 0.200 |
Why?
| | Age Factors | 2 | 2022 | 3347 | 0.200 |
Why?
| | Liver Failure | 1 | 2024 | 79 | 0.200 |
Why?
| | Metastasectomy | 1 | 2024 | 19 | 0.200 |
Why?
| | Succinimides | 1 | 2023 | 21 | 0.200 |
Why?
| | Drug Combinations | 3 | 2025 | 400 | 0.190 |
Why?
| | Nutritional Status | 1 | 2025 | 346 | 0.190 |
Why?
| | Cohort Studies | 4 | 2024 | 6077 | 0.180 |
Why?
| | Pancreaticojejunostomy | 1 | 2022 | 8 | 0.180 |
Why?
| | Cholestasis | 2 | 2022 | 217 | 0.180 |
Why?
| | Preoperative Care | 1 | 2025 | 396 | 0.180 |
Why?
| | Adenocarcinoma, Papillary | 1 | 2022 | 11 | 0.180 |
Why?
| | Anastomosis, Surgical | 4 | 2023 | 164 | 0.180 |
Why?
| | Feasibility Studies | 5 | 2025 | 1135 | 0.180 |
Why?
| | Imaging, Three-Dimensional | 1 | 2025 | 582 | 0.170 |
Why?
| | Postoperative Hemorrhage | 1 | 2023 | 106 | 0.170 |
Why?
| | Hemangiosarcoma | 1 | 2022 | 27 | 0.170 |
Why?
| | Carcinoma | 1 | 2023 | 225 | 0.170 |
Why?
| | Spleen | 1 | 2023 | 503 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 3 | 2026 | 2786 | 0.160 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 2020 | 8 | 0.160 |
Why?
| | Tumor Burden | 1 | 2022 | 326 | 0.160 |
Why?
| | Surgeons | 1 | 2025 | 351 | 0.160 |
Why?
| | Portal System | 1 | 2020 | 12 | 0.160 |
Why?
| | Stents | 2 | 2022 | 554 | 0.150 |
Why?
| | Ischemia | 1 | 2023 | 421 | 0.150 |
Why?
| | Predictive Value of Tests | 3 | 2025 | 2113 | 0.150 |
Why?
| | Hepatic Artery | 1 | 2020 | 53 | 0.150 |
Why?
| | Benchmarking | 1 | 2020 | 193 | 0.150 |
Why?
| | Orotate Phosphoribosyltransferase | 1 | 2018 | 3 | 0.140 |
Why?
| | Indocyanine Green | 1 | 2018 | 43 | 0.140 |
Why?
| | Biology | 3 | 2024 | 90 | 0.140 |
Why?
| | Consensus | 1 | 2020 | 467 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2023 | 511 | 0.140 |
Why?
| | Fluorescence | 1 | 2018 | 160 | 0.140 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1543 | 0.130 |
Why?
| | Intraoperative Care | 1 | 2018 | 68 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.130 |
Why?
| | Risk Factors | 5 | 2026 | 10921 | 0.130 |
Why?
| | Lymph Node Excision | 3 | 2024 | 174 | 0.120 |
Why?
| | Comorbidity | 1 | 2022 | 1665 | 0.120 |
Why?
| | Patient Safety | 1 | 2020 | 352 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1591 | 0.120 |
Why?
| | Fluorocarbons | 1 | 2018 | 122 | 0.120 |
Why?
| | Hospitals, University | 1 | 2016 | 178 | 0.110 |
Why?
| | Biopsy, Needle | 1 | 2016 | 183 | 0.110 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1712 | 0.110 |
Why?
| | Sex Factors | 1 | 2022 | 2107 | 0.110 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1412 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 426 | 0.110 |
Why?
| | Incidence | 3 | 2026 | 2936 | 0.110 |
Why?
| | Cell Survival | 1 | 2018 | 1105 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1432 | 0.110 |
Why?
| | DNA Repair | 1 | 2017 | 255 | 0.100 |
Why?
| | Liver | 1 | 2023 | 1864 | 0.100 |
Why?
| | Insulin | 1 | 2025 | 2525 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2017 | 376 | 0.100 |
Why?
| | Ligation | 2 | 2024 | 88 | 0.100 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 610 | 0.100 |
Why?
| | Prospective Studies | 3 | 2025 | 8123 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 970 | 0.100 |
Why?
| | Health Care Surveys | 2 | 2025 | 541 | 0.100 |
Why?
| | Carcinoembryonic Antigen | 2 | 2023 | 40 | 0.100 |
Why?
| | Young Adult | 2 | 2022 | 14330 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2025 | 2418 | 0.090 |
Why?
| | Thyrotropin | 2 | 2024 | 120 | 0.090 |
Why?
| | Splenectomy | 2 | 2023 | 61 | 0.090 |
Why?
| | Time Factors | 4 | 2026 | 7109 | 0.090 |
Why?
| | Computational Biology | 1 | 2017 | 678 | 0.090 |
Why?
| | Patient Selection | 1 | 2016 | 728 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6073 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.090 |
Why?
| | Mutation | 2 | 2023 | 4093 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2675 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3416 | 0.080 |
Why?
| | Cell Line, Tumor | 1 | 2017 | 3545 | 0.070 |
Why?
| | Apoptosis | 1 | 2017 | 2439 | 0.070 |
Why?
| | Hospital Mortality | 2 | 2024 | 1051 | 0.070 |
Why?
| | Length of Stay | 2 | 2025 | 1358 | 0.060 |
Why?
| | Polydioxanone | 1 | 2026 | 5 | 0.060 |
Why?
| | Risk Assessment | 1 | 2016 | 3712 | 0.060 |
Why?
| | Organoplatinum Compounds | 1 | 2025 | 65 | 0.060 |
Why?
| | Cytodiagnosis | 1 | 2025 | 31 | 0.060 |
Why?
| | Suture Techniques | 1 | 2026 | 138 | 0.050 |
Why?
| | Preoperative Period | 1 | 2025 | 157 | 0.050 |
Why?
| | Tissue Adhesives | 1 | 2024 | 21 | 0.050 |
Why?
| | Pancreatitis | 1 | 2025 | 146 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2025 | 143 | 0.050 |
Why?
| | Pneumonectomy | 1 | 2026 | 169 | 0.050 |
Why?
| | United States | 1 | 2021 | 16136 | 0.050 |
Why?
| | Smad4 Protein | 1 | 2023 | 33 | 0.050 |
Why?
| | Hepatic Duct, Common | 1 | 2023 | 5 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 74 | 0.050 |
Why?
| | Cattle | 1 | 2025 | 940 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2024 | 417 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2023 | 62 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 376 | 0.050 |
Why?
| | Reoperation | 1 | 2025 | 645 | 0.050 |
Why?
| | Abdomen | 1 | 2023 | 142 | 0.050 |
Why?
| | Postoperative Care | 1 | 2024 | 301 | 0.040 |
Why?
| | Adolescent | 1 | 2022 | 22557 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 250 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2024 | 693 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2024 | 1271 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2022 | 335 | 0.040 |
Why?
| | Survival Analysis | 1 | 2024 | 1378 | 0.040 |
Why?
| | Stomach | 1 | 2021 | 106 | 0.040 |
Why?
| | Plastics | 1 | 2021 | 50 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 78 | 0.040 |
Why?
| | Reproduction | 1 | 2022 | 209 | 0.040 |
Why?
| | Europe | 1 | 2021 | 421 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 319 | 0.040 |
Why?
| | Colectomy | 1 | 2020 | 119 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2023 | 530 | 0.040 |
Why?
| | Safety | 1 | 2021 | 347 | 0.040 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2018 | 19 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1763 | 0.030 |
Why?
| | Colonic Neoplasms | 1 | 2020 | 259 | 0.030 |
Why?
| | Recurrence | 1 | 2021 | 1133 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2867 | 0.030 |
Why?
| | Blood Glucose | 1 | 2025 | 2360 | 0.030 |
Why?
| | Gene Expression | 1 | 2018 | 1463 | 0.020 |
Why?
| | Palliative Care | 1 | 2022 | 1032 | 0.020 |
Why?
| | Lung | 1 | 2023 | 4122 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2018 | 1221 | 0.020 |
Why?
| | Animals | 1 | 2025 | 38107 | 0.010 |
Why?
|
|
Oba's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|